Results 1 to 10 of about 8,869 (125)
Turkderm Turkish Archives of Dermatology and Venereology, 2022 Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks.
Nilgün Atakan
doaj +5 more sources
Frontiers in Pharmacology, 2022 Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab in large sample population was unknown.
Yamin Shu, Yufeng Ding, Xucheng He
exaly +3 more sources
Secukinumab Mitigates Cisplatin-Induced Nephrotoxicity and Enhances Cisplatin Cytotoxicity in MCF-7 Cells via IL-17A/NF-κB Axis Modulation [PDF]
ToxicsObjective: The existing work was designed to appraise whether Secukinumab diminishes acute kidney injury in a Cisplatin- induced rat model and to explore the potential underlying mechanisms for this protective effect.
Faiz N. Alenezi +3 more
doaj +2 more sources
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Pharmaceuticals, 2022 Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use ...
Ashwin Kamath +2 more
exaly +3 more sources
Therapeutic Advances in Chronic Disease, 2019 Background: Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure.
Tzong-Yun Ger, Yu-Huei Huang
exaly +2 more sources
Clinics, 2021 The appropriate dosing regimens of secukinumab for psoriatic arthritis (PsA) are not well defined. We performed a meta-analysis to evaluate the efficacy and safety of different dosing regimens of secukinumab in the treatment of PsA.
Kai-Lin Zhang, Si-Yuan Hou, Dan Wu
doaj +1 more source
Secukinumab in psoriasis: A single-center experience
Turkderm Turkish Archives of Dermatology and Venereology, 2021 Background and Design: Several randomized clinical trials demonstrated the safety and efficacy of secukinumab in the systemic treatment of moderate-severe psoriasis; however, real-life data is limited.
Esra Ağaoğlu +4 more
doaj +1 more source
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada +3 more
openaire +2 more sources
Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
Pifu-xingbing zhenliaoxue zazhi, 2023 Objective To assess the clinical efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis. Methods Ninety-one patients with nail psoriasis from our hospital were randomly divided into cyclosporin group (30 cases),
Zhanhan TANG +5 more
doaj +1 more source
Arthritis Research & Therapy, 2023 Background Radiographic progression and course of inflammation over 2 years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) from the phase 3, randomized, PREVENT study are reported here.
Juergen Braun +14 more
doaj +1 more source